Crizanlizumab
ApprovedRecruitingInterest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Jun 10, 2021 → Jun 10, 2031
NCT ID
NCT04657822About Crizanlizumab
Crizanlizumab is a approved stage product being developed by Novartis for Sickle Cell Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04657822. Target conditions include Sickle Cell Disease.
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease were approved
Approved (3) Terminated (10) Active (8)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03720626 | Pre-clinical | Active |
| NCT05469828 | Phase 1/2 | Recruiting |
| NCT04662931 | Approved | Completed |
| NCT04657822 | Approved | Recruiting |
| NCT04435184 | Phase 2 | Completed |
| NCT03938454 | Phase 2 | Completed |
| NCT03474965 | Phase 2 | Completed |
| NCT03264989 | Phase 2 | Completed |
Competing Products
20 competing products in Sickle Cell Disease